Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
Department of Mathematics, Amrita School of Physical Sciences, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, Kerala, India.
Asian Pac J Cancer Prev. 2024 Aug 1;25(8):2633-2644. doi: 10.31557/APJCP.2024.25.8.2633.
The study aimed to investigate the distribution and clinicopathologic features of breast cancer patients in South India, while also examining the overall survival (OS) and identifying predictive factors affecting it. Additionally, we aimed to assess the influence of risk factors on Disease Free Survival (DFS) and Distant Disease-Free Survival (DDFS).
This retrospective cohort study on breast cancer trends used comprehensive follow-up including regular patient contact, medical record review and collaboration with healthcare providers. Patients without follow-up information for more than 12 months were contacted by telephone, while those with no follow-up after 2 years were labelled as lost to follow-up.
A total of 3256 patients were identified from a single cancer institute in India. The median follow-up time was 8.1 years. The 5-year survival rates were 89%, 84%, 85%, 88% and 10-year were 82%, 78%, 79%, 83% for luminal cancers, Triple Negative Breast Cancers, HER2 enriched and luminal with HER2 enriched respectively.
Poorer survival rates were seen among those with pT3/4 tumors, nodal involvement at diagnosis, Estrogen receptor negative status, high Ki67 proliferative index and higher TNM stage at diagnosis of the disease. Although our patients were younger and had more aggressive types of cancer, their DFS, DDFS and overall survival were comparable to other developed nations.
本研究旨在调查印度南部乳腺癌患者的分布和临床病理特征，同时探讨总生存（OS）情况，并确定影响 OS 的预测因素。此外，我们还旨在评估危险因素对无病生存（DFS）和远处无病生存（DDFS）的影响。
本回顾性队列研究调查了乳腺癌趋势，采用了全面的随访方式，包括定期与患者联系、病历审查以及与医疗保健提供者合作。对于超过 12 个月无随访信息的患者，通过电话进行联系，对于 2 年后仍无随访信息的患者，标记为失访。
从印度的一家癌症研究所共确定了 3256 名患者。中位随访时间为 8.1 年。5 年生存率分别为 89%、84%、85%、88%和 10 年生存率分别为 82%、78%、79%、83%，分别为 luminal 型癌症、三阴性乳腺癌、HER2 阳性乳腺癌和 luminal 型伴 HER2 阳性乳腺癌。
pT3/4 肿瘤、诊断时淋巴结受累、雌激素受体阴性状态、高 Ki67 增殖指数和更高的疾病诊断时 TNM 分期的患者生存率较差。尽管我们的患者年龄较小，癌症类型更为侵袭性，但他们的 DFS、DDFS 和总生存与其他发达国家相当。
